Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ATYR PHARMA, INC.

(LIFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Health Care Stocks Still Adding to Afternoon Slide

09/13/2021 | 03:46pm EDT


ę MT Newswires 2021
All news about ATYR PHARMA, INC.
10/12ATYR PHARMA : RBC Initiates aTyr Pharma at Outperform, Speculative Risk, Sets Price Target..
MT
10/11ATYR PHARMA : to Participate in Piper Sandler Investor Lung Day
AQ
10/06ATYR PHARMA : Announces Appointment of Robert W. Ashworth, PhD, as Vice President of Regul..
AQ
10/01ATYR PHARMA : Announces Poster Presentation at the Society for Immunotherapy of Cancer Ann..
AQ
09/21ATYR PHARMA : Piper Sandler Starts aTyr Pharma at Overweight With $19 Price Target
MT
09/20aTyr Pharma Announces Closing of $86.3 Million Public Offering Including Full Exercise ..
GL
09/17ATYR PHARMA : Prices Offering at $8/Share
MT
09/16ATYR PHARMA : Announces Pricing of $75 million Public Offering of Common Stock (Form 8-K)
PU
09/16ATYR PHARMA INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/16ATYR PHARMA : to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summ..
AQ
More news
Analyst Recommendations on ATYR PHARMA, INC.
More recommendations
Financials (USD)
Sales 2021 2,53 M - -
Net income 2021 -37,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,03x
Yield 2021 -
Capitalization 235 M 235 M -
Capi. / Sales 2021 92,6x
Capi. / Sales 2022 55,6x
Nbr of Employees 42
Free-Float 97,5%
Chart ATYR PHARMA, INC.
Duration : Period :
aTyr Pharma, Inc. Technical Analysis Chart | LIFE | US0021202025 | MarketScreener
Technical analysis trends ATYR PHARMA, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 8,47 $
Average target price 19,67 $
Spread / Average Target 132%
EPS Revisions
Managers and Directors
Sanjay S. Shukla President, Chief Executive Officer & Director
Jill M. Broadfoot Chief Financial Officer
John K. Clarke Chairman
Leslie Nangle Vice President-Research
Paul R. Schimmel Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ATYR PHARMA, INC.118.30%235
MODERNA, INC.230.95%139 557
LONZA GROUP AG32.63%60 898
IQVIA HOLDINGS INC.42.93%48 923
SEAGEN INC.1.46%32 330
CELLTRION, INC.-38.02%26 036